Tags

Type your tag names separated by a space and hit enter

The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study.
Aliment Pharmacol Ther 2005; 22(5):381-5AP

Abstract

BACKGROUND

Irritable bowel syndrome has been treated with selective serotonin reuptake inhibitors but there is not enough evidence from controlled trials to prove their effectiveness.

AIM

To compare the effects of fluoxetine and placebo in the treatment of pain and constipation-predominant irritable bowel syndrome in a double-blind randomized-controlled trial.

METHODS

Forty-four cases meeting Rome II criteria for irritable bowel syndrome with predominance of pain and constipation were included in this study. Organic causes were ruled out by detailed history, physical examination, laboratory tests and colonoscopy. Participants were then randomly assigned to receive either fluoxetine or placebo for 12 weeks. Symptoms addressed by the Rome II criteria were recorded during treatment and 4 weeks after termination of treatment.

RESULTS

Fluoxetine was significantly more effective than placebo in decreasing abdominal discomfort, relieving feeling and sense of bloating, increasing frequency of bowel movements and decreasing consistency of stool. Mean number of symptoms per patient decreased from 4.6 to 0.7 in the fluoxetine group vs. 4.5 to 2.9 in controls (P < 0.001).

CONCLUSIONS

Fluoxetine is an effective and well-tolerated short-term treatment for pain and constipation-predominant irritable bowel syndrome.

Authors+Show Affiliations

Digestive Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16128675

Citation

Vahedi, H, et al. "The Effect of Fluoxetine in Patients With Pain and Constipation-predominant Irritable Bowel Syndrome: a Double-blind Randomized-controlled Study." Alimentary Pharmacology & Therapeutics, vol. 22, no. 5, 2005, pp. 381-5.
Vahedi H, Merat S, Rashidioon A, et al. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther. 2005;22(5):381-5.
Vahedi, H., Merat, S., Rashidioon, A., Ghoddoosi, A., & Malekzadeh, R. (2005). The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Alimentary Pharmacology & Therapeutics, 22(5), pp. 381-5.
Vahedi H, et al. The Effect of Fluoxetine in Patients With Pain and Constipation-predominant Irritable Bowel Syndrome: a Double-blind Randomized-controlled Study. Aliment Pharmacol Ther. 2005 Sep 1;22(5):381-5. PubMed PMID: 16128675.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. AU - Vahedi,H, AU - Merat,S, AU - Rashidioon,A, AU - Ghoddoosi,A, AU - Malekzadeh,R, PY - 2005/9/1/pubmed PY - 2005/11/15/medline PY - 2005/9/1/entrez SP - 381 EP - 5 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 22 IS - 5 N2 - BACKGROUND: Irritable bowel syndrome has been treated with selective serotonin reuptake inhibitors but there is not enough evidence from controlled trials to prove their effectiveness. AIM: To compare the effects of fluoxetine and placebo in the treatment of pain and constipation-predominant irritable bowel syndrome in a double-blind randomized-controlled trial. METHODS: Forty-four cases meeting Rome II criteria for irritable bowel syndrome with predominance of pain and constipation were included in this study. Organic causes were ruled out by detailed history, physical examination, laboratory tests and colonoscopy. Participants were then randomly assigned to receive either fluoxetine or placebo for 12 weeks. Symptoms addressed by the Rome II criteria were recorded during treatment and 4 weeks after termination of treatment. RESULTS: Fluoxetine was significantly more effective than placebo in decreasing abdominal discomfort, relieving feeling and sense of bloating, increasing frequency of bowel movements and decreasing consistency of stool. Mean number of symptoms per patient decreased from 4.6 to 0.7 in the fluoxetine group vs. 4.5 to 2.9 in controls (P < 0.001). CONCLUSIONS: Fluoxetine is an effective and well-tolerated short-term treatment for pain and constipation-predominant irritable bowel syndrome. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/16128675/The_effect_of_fluoxetine_in_patients_with_pain_and_constipation_predominant_irritable_bowel_syndrome:_a_double_blind_randomized_controlled_study_ L2 - https://doi.org/10.1111/j.1365-2036.2005.02566.x DB - PRIME DP - Unbound Medicine ER -